nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses
|
Kline, Kathryn A. F. |
|
|
|
5 |
p. 384-393 |
artikel |
2 |
Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions
|
DiNardo, Courtney |
|
2019 |
|
5 |
p. 386-394 |
artikel |
3 |
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia
|
Krecak, Ivan |
|
|
|
5 |
p. 155-169 |
artikel |
4 |
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases
|
Duminuco, Andrea |
|
|
|
5 |
p. 176-189 |
artikel |
5 |
ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms
|
Sullivan, Mia J. |
|
|
|
5 |
p. 105-112 |
artikel |
6 |
Application of Next-Generation Sequencing-Based Mutational Profiling in Acute Lymphoblastic Leukemia
|
Aleem, Ahmed |
|
|
|
5 |
p. 394-404 |
artikel |
7 |
Approach to MPN Symptom Assessment
|
Geyer, Holly |
|
2017 |
|
5 |
p. 381-388 |
artikel |
8 |
Avapritinib in the Treatment of Systemic Mastocytosis: an Update
|
Below, Samantha |
|
|
|
5 |
p. 464-472 |
artikel |
9 |
BTK Inhibitors in Chronic Lymphocytic Leukemia
|
Gaballa, Sameh |
|
|
|
5 |
p. 422-432 |
artikel |
10 |
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
|
Pehlivan, Katherine C. |
|
2018 |
|
5 |
p. 396-406 |
artikel |
11 |
Challenges in Chronic Myeloid Leukemia Management in South America
|
Pagnano, Katia B. |
|
|
|
5 |
p. 440-447 |
artikel |
12 |
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You
|
Ruella, Marco |
|
2016 |
|
5 |
p. 368-384 |
artikel |
13 |
Chromatin-Remodeled State in Lymphoma
|
Liu, Yuxuan |
|
2019 |
|
5 |
p. 439-450 |
artikel |
14 |
Chronic Myeloid Leukemia—the Promise of Tyrosine Kinase Inhibitor Discontinuation
|
Narra, Ravi Kishore |
|
2017 |
|
5 |
p. 415-423 |
artikel |
15 |
Circulating Tumor Cells: State-of-the-art Update on Technologies and Clinical Applications
|
Yap, Kristofor |
|
2019 |
|
5 |
p. 353-357 |
artikel |
16 |
Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis
|
Baird, John H. |
|
2018 |
|
5 |
p. 407-416 |
artikel |
17 |
Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes
|
Drusbosky, Leylah M. |
|
2017 |
|
5 |
p. 478-483 |
artikel |
18 |
Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms
|
Foucar, Charles Elliott |
|
2017 |
|
5 |
p. 406-414 |
artikel |
19 |
Elevating Twitter-Based Journal Club Discussions by Leveraging a Voice-Based Platform: #HemepathJC Meets Clubhouse
|
Ahmed, Aadil |
|
|
|
5 |
p. 418-421 |
artikel |
20 |
Emerging EZH2 Inhibitors and Their Application in Lymphoma
|
Lue, Jennifer K. |
|
2018 |
|
5 |
p. 369-382 |
artikel |
21 |
Familial MPN Predisposition
|
Tashi, Tsewang |
|
2017 |
|
5 |
p. 442-447 |
artikel |
22 |
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions
|
Sears-Smith, Megan |
|
|
|
5 |
p. 158-166 |
artikel |
23 |
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms
|
Badar, Talha |
|
|
|
5 |
p. 113-120 |
artikel |
24 |
How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera
|
Reiter, Andreas |
|
2016 |
|
5 |
p. 356-367 |
artikel |
25 |
IMiDs New and Old
|
Yamshon, Samuel |
|
2019 |
|
5 |
p. 414-425 |
artikel |
26 |
Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies
|
Falchi, Lorenzo |
|
2017 |
|
5 |
p. 484-494 |
artikel |
27 |
Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection
|
Sukswai, Narittee |
|
2019 |
|
5 |
p. 368-375 |
artikel |
28 |
Investigation and Management of Erythrocytosis
|
McMullin, Mary Frances |
|
2016 |
|
5 |
p. 342-347 |
artikel |
29 |
Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer
|
Achi, Hanadi El |
|
2019 |
|
5 |
p. 358-367 |
artikel |
30 |
Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia
|
Nazha, Aziz |
|
2018 |
|
5 |
p. 341-347 |
artikel |
31 |
Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia
|
Hammond, Danielle |
|
|
|
5 |
p. 405-417 |
artikel |
32 |
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera
|
How, Joan |
|
|
|
5 |
p. 473-482 |
artikel |
33 |
Management of Chronic Myeloid Leukemia in Children and Young Adults
|
Ford, Maegan |
|
|
|
5 |
p. 121-126 |
artikel |
34 |
Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials
|
Stein, Brady L. |
|
|
|
5 |
p. 483-489 |
artikel |
35 |
Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies
|
Torka, Pallawi |
|
2019 |
|
5 |
p. 426-438 |
artikel |
36 |
Minimal Residual Disease Eradication in CML: Does It Really Matter?
|
Tantravahi, Srinivas K. |
|
2017 |
|
5 |
p. 495-505 |
artikel |
37 |
Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS
|
Nazha, Aziz |
|
2017 |
|
5 |
p. 461-467 |
artikel |
38 |
Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors
|
Yaghmaie, Marjan |
|
2019 |
|
5 |
p. 395-404 |
artikel |
39 |
Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender
|
Patterson-Fortin, Jeffrey |
|
2017 |
|
5 |
p. 424-431 |
artikel |
40 |
Multiple Myeloma: Current Clinical Landscape and Compounding Costs
|
Beck, Kelsey |
|
|
|
5 |
p. 201-215 |
artikel |
41 |
Multi-Specific CAR Targeting to Prevent Antigen Escape
|
Walsh, Zachary |
|
2019 |
|
5 |
p. 451-459 |
artikel |
42 |
Navigating Ethical Practices in the Era of High Cost Hematology
|
Ertz-Archambault, Natalie |
|
|
|
5 |
p. 401-407 |
artikel |
43 |
Non-Pharmacologic Management of Splenomegaly for Patients with Myelofibrosis: Is There Any Role for Splenectomy or Splenic Radiation in 2020?
|
Sankar, Kamya |
|
|
|
5 |
p. 391-400 |
artikel |
44 |
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors
|
Waksal, Julian A. |
|
|
|
5 |
p. 140-154 |
artikel |
45 |
Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors
|
Economides, Minas P. |
|
2019 |
|
5 |
p. 460-468 |
artikel |
46 |
Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics
|
Shaver, Aaron C. |
|
2017 |
|
5 |
p. 448-454 |
artikel |
47 |
Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times
|
Patel, Sagar S. |
|
2017 |
|
5 |
p. 455-460 |
artikel |
48 |
Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic
|
Barbui, Tiziano |
|
|
|
5 |
p. 455-463 |
artikel |
49 |
Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing
|
Zuo, Zhuang |
|
2019 |
|
5 |
p. 376-385 |
artikel |
50 |
Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature
|
Zhou, Amy |
|
2017 |
|
5 |
p. 397-405 |
artikel |
51 |
Real-world Management of CML: Outcomes and Treatment Patterns
|
Held, Nicole |
|
|
|
5 |
p. 167-175 |
artikel |
52 |
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
|
Dao, Kim-Hien T. |
|
2017 |
|
5 |
p. 432-441 |
artikel |
53 |
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
|
Odetola, Oluwatobi |
|
|
|
5 |
p. 130-143 |
artikel |
54 |
Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma
|
Teo, Winnie Z. Y. |
|
|
|
5 |
p. 190-200 |
artikel |
55 |
Richter Transformation of Chronic Lymphocytic Leukemia—Are We Making Progress?
|
Audil, Hadiyah Y. |
|
|
|
5 |
p. 144-157 |
artikel |
56 |
Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis
|
Martin, Karlyn |
|
2017 |
|
5 |
p. 389-396 |
artikel |
57 |
Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma
|
Rhodes, Joanna |
|
2018 |
|
5 |
p. 356-368 |
artikel |
58 |
Social Media for Hematopathologists: Medical Practice Reinvented—#Hemepath
|
El Hussein, S. |
|
|
|
5 |
p. 383-390 |
artikel |
59 |
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations
|
Yuan, Ji |
|
|
|
5 |
p. 121-129 |
artikel |
60 |
Strategies for Predicting Response to Checkpoint Inhibitors
|
Zappasodi, Roberta |
|
2018 |
|
5 |
p. 383-395 |
artikel |
61 |
Targeting BCMA in Multiple Myeloma
|
Tan, Carlyn Rose |
|
|
|
5 |
p. 367-383 |
artikel |
62 |
The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML)
|
Wolfe, Heather R. |
|
|
|
5 |
p. 448-454 |
artikel |
63 |
Therapy for Chronic Myelomonocytic Leukemia in a New Era
|
Moyo, Tamara K. |
|
2017 |
|
5 |
p. 468-477 |
artikel |
64 |
The Role of PI3K Inhibition in Lymphoid Malignancies
|
Keudell, Gottfried von |
|
2019 |
|
5 |
p. 405-413 |
artikel |
65 |
The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
|
Birgegård, Gunnar |
|
2016 |
|
5 |
p. 348-355 |
artikel |
66 |
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
|
Mora, Barbara |
|
|
|
5 |
p. 127-139 |
artikel |
67 |
Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update
|
Bhatnagar, Neha |
|
2016 |
|
5 |
p. 333-341 |
artikel |
68 |
Treatment-Free Remission: the New Goal in CML Therapy
|
Atallah, Ehab |
|
|
|
5 |
p. 433-439 |
artikel |
69 |
Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances
|
Vrooman, Lynda M. |
|
2016 |
|
5 |
p. 385-394 |
artikel |
70 |
Updates on Circulating Tumor DNA Assessment in Lymphoma
|
Darrah, Justin M. |
|
2018 |
|
5 |
p. 348-355 |
artikel |
71 |
Venetoclax for the Treatment of Chronic Lymphocytic Leukemia
|
Eradat, Herbert |
|
2019 |
|
5 |
p. 469-476 |
artikel |
72 |
What Is the Optimal Induction Therapy for Younger Fit Patients With AML?
|
Fernandez, Hugo F. |
|
2016 |
|
5 |
p. 327-332 |
artikel |